Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mitoxantrone for refractory and relapsed acute leukemia.

W R Bezwoda1, C Bernasconi, R M Hutchinson

  • 1Department of Medicine, Haematology/Oncology, University of the Witwatersrand, Johannesburg, South Africa.

Cancer
|August 1, 1990
PubMed
Summary

Mitoxantrone effectively treats acute leukemia, achieving complete remission in 40% of patients. This agent shows promise for first-line therapy in acute nonlymphocytic leukemia (ANLL) with manageable side effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

SAS CARE 2 - a randomized study of CPAP in patients with obstructive sleep disordered breathing following ischemic stroke or transient ischemic attack.

Sleep medicine: X·2021
Same author

Smartphone-based remote assessment of upper extremity function for multiple sclerosis using the Draw a Shape Test.

Physiological measurement·2020
Same author

Stimulation of the globus pallidus internus in the treatment of Parkinson's disease: Long-term results of a monocentric cohort.

Parkinsonism & related disorders·2019
Same author

Quantitative electroencephalography supports diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy.

Journal of neurovirology·2018
Same author

Hodgkin's Disease in 50 Intravenous Drug Users with HIV-Infection.

Leukemia & lymphoma·2016
Same author

Tacrolimus predose concentrations do not predict the risk of acute rejection after renal transplantation: a pooled analysis from three randomized-controlled clinical trials(†).

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2013

Area of Science:

  • Oncology
  • Hematology
  • Pharmacology

Background:

  • Acute leukemia, including acute nonlymphocytic leukemia (ANLL) and acute lymphocytic leukemia (ALL), presents significant treatment challenges, particularly in relapsed or refractory cases.
  • Chronic myeloid leukemia (CML) in its acute blastic phase also requires effective therapeutic options.
  • Existing treatments may have limitations, necessitating the exploration of novel chemotherapeutic agents.

Purpose of the Study:

  • To evaluate the efficacy and safety of mitoxantrone in patients with relapsed or refractory acute leukemia.
  • To assess the response rates, duration of response, and survival in this patient population.
  • To determine the potential role of mitoxantrone in the treatment of acute leukemia, including its cross-resistance profile.

Main Methods:

Related Experiment Videos

  • An open-label Phase II study was conducted involving 80 patients with relapsed or refractory acute leukemia and 3 with acute blastic CML.
  • Mitoxantrone was administered intravenously at a dose of 12 mg/m2 daily for 5 consecutive days.
  • Complete remission (CR) rates, duration of response, survival data, and toxicity profiles were meticulously recorded.

Main Results:

  • A 40% complete remission (CR) rate was observed in 32 out of 80 patients.
  • Specific CR rates included 52% for relapsed ANLL, 33% for relapsed ALL, 24% for daunorubicin + cytosine arabinoside refractory ANLL, and 33% for refractory ALL.
  • No CR was achieved in patients with acute blastic CML. Median survival was 121 days, with a median response duration of 303 days.
  • Toxicity was generally mild, characterized by manageable hematologic suppression and tolerable side effects.

Conclusions:

  • Mitoxantrone is an active chemotherapeutic agent in the treatment of acute leukemia, demonstrating efficacy in relapsed and refractory settings.
  • The drug exhibits incomplete cross-resistance with daunorubicin, suggesting its utility in patients who have not responded to or have relapsed after anthracycline therapy.
  • Mitoxantrone should be considered as a potential first-line therapy option for ANLL, given its activity and acceptable toxicity profile.